Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;25(1):e14179.
doi: 10.1002/acm2.14179. Epub 2023 Nov 27.

The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac

Affiliations

The impact of margin reduction on radiation dose distribution of ultra-hypofractionated prostate radiotherapy utilizing a 1.5-T MR-Linac

Cem Onal et al. J Appl Clin Med Phys. 2024 Jan.

Abstract

Background: We examined the effects of reducing the planning target volume (PTV) margin in MR-guided radiotherapy (MRgRT) on the distribution of radiation dose to target volumes and organs-at-risk (OARs). Thus, we compared MR-Linac (MRL) plans with and without reduced margin and intensity-modulated radiotherapy (IMRT) plan with conventional linac for low-risk prostate cancer patients receiving 36.25 Gy in five fractions of ultra-hypofractionated radiation therapy.

Materials and methods: Twenty low-risk prostate cancer patients treated with 1.5 T MR-Linac were evaluated. The same planning CT images were used for four plans: the MRL-R plan with reduced margin planning target volume (PTV-R) and the MRL-N plan with normal margin PTV (PTV-N), which is also used for IMRT plan. In four plans, PTV doses, organs-at-risk (OARs) doses, the homogeneity index (HI), and monitor units were compared.

Results: All plans met the criteria for PTV coverage and OARs dose constraints. The maximum and mean PTV doses were significantly higher in the MRL-R and MRL-N plans compared to the IMRT plan. The HI was lowest in the IMRT plan (0.040 ± 0.013) and highest in the MRL-N plan (0.055 ± 0.012; p < 0.001). There was no significant difference in the PTV dosimetric parameters between the MRL-R and the MRL-N plans. The high doses in the rectum was significantly lower in the MRL-R compared to other plans. The bladder V36.25 Gy was significantly lower in the MRL-R plan (2.43 ± 1.87 Gy) compared to MRL-N (4.50 ± 2.42 Gy; p < 0.001), and IMRT plans (4.76 ± 2.77 Gy; p < 0.001). There was no significant difference in the low-dose volumes of the body, maximum femur doses, or monitor units across each plan.

Conclusions: Ultra-hypofractionated MR-guided RT with 1.5 T MRL is dosimetrically feasible for patients with prostate cancer. The improved soft tissue contrast and the online adaptive plan for 1.5 T MR-Linac allows for PTV margin reduction resulted in a significant dose reduction in OARs.

Keywords: MR-linac; dosimetry; prostate cancer; radiotherapy; stereotactic body radiotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

FIGURE 1
FIGURE 1
Prostate (green line), PTV with reduced margin (yellow line) and PTV with standard margins demonstrated in (a) axial, (b) sagittal, (c) coronal CT slices, and (d) beams‐eye‐view reconstruction.
FIGURE 2
FIGURE 2
Representative axial CT slices showing 95% of prescribed dose distributions (green area) for the (a) MR‐Linac plan with reduced margin (MRL‐R), (b) MR‐Linac plan with normal margin (MRL‐N), and (c) intensity‐modulated radiotherapy plan and 50% of prescribed dose distributions (blue area) for the (d–f) same consecutive plans (red area represents 95% isodose area).
FIGURE 3
FIGURE 3
Box and whisker plot demonstrating rectum and bladder doses according to the dose volume parameters across each plan.
FIGURE 4
FIGURE 4
Box and whisker plot demonstrating rectum, bladder and femur doses received by 1 cc volume and mean doses measured in four different plans.

References

    1. Lukka HR, Pugh SL, Bruner DW, et al. Patient reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys. 2018;102(2):287‐295. - PMC - PubMed
    1. Lukka HR, Deshmukh S, Bruner DW, et al. Five‐year patient‐reported outcomes in NRG oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer. Int J Radiat Oncol Biol Phys. 2023;116(4):770‐778. - PMC - PubMed
    1. Lagendijk JJ, Raaymakers BW, Raaijmakers AJ, et al. MRI/linac integration. Radiother Oncol. 2008;86(1):25‐29. - PubMed
    1. Kim JI, Park JM, Choi CH, An HJ, Kim YJ, Kim JH. Retrospective study comparing MR‐guided radiation therapy (MRgRT) setup strategies for prostate treatment: repositioning vs. replanning. Radiat Oncol. 2019;14(1):139. - PMC - PubMed
    1. Da Silva Mendes V, Nierer L, Li M, et al. Dosimetric comparison of MR‐linac‐based IMRT and conventional VMAT treatment plans for prostate cancer. Radiat Oncol. 2021;16(1):133. - PMC - PubMed